(2R,5S)-2-(2,4-二氧代-3,4-二氢-1(2H)-嘧啶基)-5-({[羟基({羟基[(氧代膦基)氧基]磷酰}氧基)磷酰]氧基}甲基)四氢呋喃-3,4-二基 | 108321-53-5

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷酸
• 中文名称: (2R,5S)-2-(2,4-二氧代-3,4-二氢-1(2H)-嘧啶基)-5-({[羟基({羟基[(氧代膦基)氧基]磷酰}氧基)磷酰]氧基}甲基)四氢呋喃-3,4-二基
• 中文别名: 尿苷-5'-三磷酸三盐
• 英文名称: Uridine 5'-triphosphate tris salt
• 英文别名: 2-amino-2-(hydroxymethyl)propane-1,3-diol;[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
• CAS: 108321-53-5
• 化学式: C13H26N3O18P3
• mdl: MFCD00058360
• 分子量: 605.28
• InChiKey: NHMNWWVJZZPKSL-IAIGYFSYSA-N

物化性质

• 溶解度：
  在水中的溶解度为50mg/mL，透明，无色
• 碰撞截面：
  190.2 Ų [M-2H+Na]-; 180.1 Ų [M-H]-; 186.9 Ų [M+H]+; 188.5 Ų [M+Na]+

计算性质

• 辛醇/水分配系数(LogP)：
  -3.38
• 重原子数：
  37
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.692
• 拓扑面积：
  346
• 氢给体数：
  11
• 氢受体数：
  19

安全信息

• 危险品标志：
  T
• 危险类别码：
  R23/24/25,R36/37/38

制备方法与用途

生物活性

尿苷-5'-三磷酸三钠盐是一种内源性代谢产物。

文献信息

• UTP FOR THE DIAGNOSIS OF STENOSES AND OTHER CONDITIONS OF RESTRICTED BLOOD FLOW
  申请人：P2-Science Aps

  公开号：EP2464278A1

  公开（公告）日：2012-06-20
• URIDINE PHOSPHORYLASE (UPASE) INHIBITORS FOR TREATMENT OF LIVER CONDITIONS
  申请人：Tosk, Inc.

  公开号：EP3986409A1

  公开（公告）日：2022-04-27
• Use of UTP for the diagnosis of stenoses and other conditions of restricted blood flow
  申请人：Rosenmeier Jaya Brigitte

  公开号：US20110085977A1

  公开（公告）日：2011-04-14

  The present invention relates to methods for determining whether blood flow is restricted in a blood vessel of an individual suspected of compromised blood flow in the vessel, the method comprising the steps of delivering UTP, a derivative thereof, or a salt thereof to the vessel, assessing blood flow quantitatively in the vessel by obtaining a value that correlates to blood flow in said vessel, comparing the obtained value with a reference value, and determining whether the individual has compromised blood flow based on the results of the comparison. The invention also provides for methods of diagnosing atherosclerotic and ischemic heart diseases using UTP, a derivative thereof, or a salt thereof, as well as methods for inducing maximal hyperemia for diagnostic purposes.
• Methods for Treating Fatty Liver Disease
  申请人：Pizzorno Giuseppe

  公开号：US20120294869A1

  公开（公告）日：2012-11-22

  The present invention relates to the compositions, formulations and methods of treating fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and their sequelae by administration of uridine or a compound that modulates one or more uridine phosphorylases in a subject in need thereof.
• USE OF UTP FOR THE DIAGNOSIS OF STENOSES AND OTHER CONDITIONS OF RESTRICTED BLOOD FLOW
  申请人：ROSENMEIER Jaya Brigitte

  公开号：US20130216481A1

  公开（公告）日：2013-08-22

  The present invention relates to methods for determining whether blood flow is restricted in a blood vessel of an individual suspected of compromised blood flow in the vessel, the method comprising the steps of delivering UTP, a derivative thereof, or a salt thereof to the vessel, assessing blood flow quantitatively in the vessel by obtaining a value that correlates to blood flow in said vessel, comparing the obtained value with a reference value, and determining whether the individual has compromised blood flow based on the results of the comparison. The invention also provides for methods of diagnosing atherosclerotic and ischemic heart diseases using UTP, a derivative thereof, or a salt thereof, as well as methods for inducing maximal hyperemia for diagnostic purposes.